
    
      The MEDI8852 phase 2b study will evaluate the efficacy and safety of a single intravenous
      (IV) dose of MEDI8852 or placebo administered in conjunction with oseltamivir in adult
      subjects who are hospitalized with influenza caused by Type A strains. Approximately 450
      subjects will be enrolled at study centers in North America, Europe, and other regions.
    
  